Showing results (41-50 of 113) with videos related to

Sort By:
Pageof 12
Journal of Human Hypertension|September 16, 2011
Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: comparison between hypertensive and normotensive subjects with and without HIV infectionA M Grandi, E Nicolini, M Giola, et al.
Frontiers in Immunology|December 2, 2024
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapyAmandine Decroos, Sarah Meddour, Marine Demoy, et al.
Leukemia & Lymphoma|October 26, 2011
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisisFranck E Nicolini, Tamas Masszi, Zhixiang Shen, et al.
Blood|December 3, 2010
Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemiaErika Cosset, Ghassan Hamdan, Sandrine Jeanpierre, et al.
British Journal of Haematology|April 11, 2016
Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional studyGabriel Etienne, Francoise Huguet, Agnès Guerci-Bresler, et al.
Cancer|July 7, 2011
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phaseFranck E Nicolini, Anna Turkina, Zhi-Xiang Shen, et al.
Cancer|May 28, 2024
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseFadi G Haddad, Koji Sasaki, Lewis Nasr, et al.
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Blood|August 17, 2012
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutationJorge Cortes, Jeff H Lipton, Delphine Rea, et al.
American Journal of Hematology|March 8, 2013
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitorsJ Cortes, R Digumarti, P M Parikh, et al.
Pageof 12